Key facts
- This page summarizes Denali Capital Global Investments LLC's Form 4 filing for Denali Capital Acquisition Corp. (DNQAF).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 16 Sep 2024, 10:05.
Denali Capital Global Investments LLC - 30 Aug 2024 Form 4 Insider Report for Denali Capital Acquisition Corp. (DNQAF)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- DNQAF
- Reported as of
- 30 Aug 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 16 Sep 2024, 10:05:57 UTC
- Prior SEC filing
- 24 May 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jiandong Xu, Manager and Controlling Member of Denali Capital Global Investments LLC
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Denali Capital Global Investments LLC filed Form 4 for Denali Capital Acquisition Corp. (DNQAF) on 16 Sep 2024.
Change
- Previous filing in this sequence was filed on 24 May 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
DECA
transaction
Derivative
Class B Ordinary Shares
Sale
- Transaction value
- Shares
- -500,000
- Change %
- -26%
- Price
- Shares after
- 1,432,500
- Date
- 30 Aug 2024
- Ownership
- Direct
- Underlying class
- Class B Ordinary Shares
- Underlying amount
- 500,000
- Exercise price
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The Class B ordinary shares will automatically convert into Class A Ordinary Shares, par value $0.0001 per share ("Class A Ordinary Shares"), of the Issuer concurrently with or immediately following the consummation of the Issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to adjustment.
Footnote F2
On August 30, 2024, (i) the Issuer, Denali Merger Sub Inc., and Semnur Pharmaceuticals, Inc. ("Semnur"), a Delaware corporation and wholly owned subsidiary of Scilex Holding Company ("Scilex") entered into an agreement and plan of merger and (ii) the Reporting Person and Scilex entered into a Sponsor Interest Purchase Agreement (the "SIPA"). Pursuant to the SIPA, Scilex agreed to purchase 500,000 Class B ordinary shares of the Issuer held by the Reporting Person for aggregate consideration of (i) $2,000,000 (the "Cash Consideration") and (ii) 300,000 shares of common stock, par value $0.0001 per share, of Scilex (the "Scilex Shares"). Pursuant to the SIPA, Scilex paid the Cash Consideration to the Reporting Person on August 30, 2024 and has agreed to issue the Scilex Shares to the Reporting Person contingent upon and following the occurrence of the effective time of the Merger.